Evofem Biosciences, Inc.
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
EVFM$0.48-23.4%Stored close · as of Aug 10, 2022
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
EXHIBIT INDEX
| Exhibit · Filed · Incorporated by Reference | ||||||
|---|---|---|---|---|---|---|
| No. · Exhibit Title · Herewith · Form · File No. · Date Filed | ||||||
| 2.1 | Amended and Restated Plan of Merger, by and between the Company, Aditxt, Inc. and Adifem, Inc. | 8-K | 001-36754 | 7/18/2024 | ||
| 2.2 | First Amendment to the Amended and Restated Agreement and Plan of Merger, by and between the Company, Aditxt, Inc., and Adifem, Inc., dated August 16, 2024 | 8-K | 001-36754 | 8/20/2024 | ||
| 2.3 | Second Amendment to the Amended and Restated Agreement and Plan of Merger, by and between the Company, Aditxt, Inc., and Adifem, Inc., dated September 6, 2024 | 8-K | 001-36754 | 9/6/2024 | ||
| 2.4 | Third Amendment to the Amended and Restated Agreement and Plan of Merger, by and among the Company, Aditxt, Inc. and Adifem, Inc., dated October 2, 2024 | 8-K | 001-36754 | 10/3/2024 | ||
| 2.5 | Fourth Amendment to the Amended and Restated Agreement and Plan of Merger, by and among the Company, Aditxt, Inc. and Adifem, Inc., dated November 19, 2024 | 8-K | 001-36754 | 11/25/2024 | ||
| 2.6 | Fifth Amendment to the Amended and Restated Agreement and Plan of Merger by and among the Company, Aditxt, Inc. and Adifem, Inc., dated March 22, 2025 | 10-K | 001-36754 | 3/24/2025 | ||
| 2.7 | Sixth Amendment to the Amended and Restated Merger Agreement, dated August 26, 2025 | 8-K | 001-36754 | 8/26/2025 | ||
| 3.1 | Certificate of Designations of the Series G-1 Preferred Stock | 8-K | 001-36754 | 8/26/2025 | ||
| 10.1 | License and Supply Agreement dated March 20, 2025 | 8-K | 001-36754 | 3/26/2025 | ||
| 10.2 | Amendment No. 1 to License and Supply Agreement dated March 20, 2025 | 8-K | 001-36754 | 4/3/2025 | ||
| 10.3 | Form of Securities Purchase Agreement | 8-K | 001-36754 | 7/2/2025 | ||
| 10.4 | Form of Senior Subordinated Convertible Note | 8-K | 001-36754 | 7/2/2025 | ||
| 10.5 | Form of Warrant | 8-K | 001-36754 | 7/2/2025 | ||
| 10.6 | Form of Call Option Agreement | 8-K | 001-36754 | 4/14/2025 | ||
| 10.7 | First Amendment to Development and Supply Agreement dated May 3, 2025 | 8-K | 001-36754 | 5/8/2025 | ||
| 10.8 | License Agreement by and between the Company and Pharma 1 Drug Store, L.L.C | 8-K | 001-36754 | 5/22/2025 | ||
| 10.9 | Form of Exchange Agreement | 8-K | 001-36754 | 8/26/2025 | ||
| 10.10 | Third Amendment to Securities Purchase Agreement dated as of October 13, 2025 | 8-K | 001-36754 | 10/17/2025 | ||
| 31.1 | * | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | |||
| 31.2 | * | Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | |||
| 32.1 | * | Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | X | |||
| 101.INS | † | Inline XBRL Instance Document | X | |||
| 101.SCH | † | Inline XBRL Taxonomy Extension Schema Document | X | |||
| 101.CAL | † | Inline XBRL Taxonomy Extension Calculation Linkbase Document | X | |||
| 101.DEF | † | Inline XBRL Definition Linkbase Document | X | |||
| 101.LAB | † | Inline XBRL Taxonomy Extension Labels Linkbase Document | X | |||
| 101.PRE | † | Inline XBRL Taxonomy Extension Presentation Linkbase Document | X | |||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | X | ||||
| * | Furnished herewith. This certification is being furnished solely to accompany this report pursuant to 18 U.S.C. 1350, and are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation by reference language in such filing. |
|---|---|
| † | The financial information of Evofem Biosciences, Inc. Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 filed on November 13, 2025 formatted in XBRL (Extensible Business Reporting Language): (i) the Condensed Consolidated Balance Sheets, (ii) Parenthetical Data to the Condensed Consolidated Balance Sheets, (iii) the Condensed Consolidated Statements of Operations, (iv) the Condensed Consolidated Statements of Convertible and Redeemable Preferred Stock and Stockholders’ Deficit, (v) the Condensed Consolidated Statements of Cash Flows, and (vi) Notes to Unaudited Condensed Consolidated Financial Statements, is furnished electronically herewith. |
| ^^ | Certain exhibits and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish supplementally a copy of any omitted exhibit or schedule upon request by the SEC. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.